CellRep

Reprogramming exhausted cells to transform cancer immunotherapy

United States · Founded 2024 · $425K raised

Employees
1–10
Founded
2024
Business Model
B2B
Total Funding
$425K
Last Round
$425K AngelMay 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

CellRep is a biotechnology company founded in 2024 that develops an AI-powered platform to discover small molecules that rejuvenate exhausted T cells without genetic modification, targeting the critical failure of CAR-T therapy against solid tumors. The platform operates across in silico (AI screening of over one billion candidate molecules), in vitro (human T cell functional assays), and in vivo (preclinical tumor models) dimensions to identify compounds that restore immune cell polyfunctionality, persistence, and metabolic fitness. CellRep's lead program has demonstrated 6.6x improvement in T cell polyfunctionality and 90.5% antitumor capacity against HER2+ solid tumors, with first-in-human trials planned at Baylor College of Medicine in 2026.

Summary

CellRep is an Artificial Intelligence company based in United States, founded in 2024. It has raised $425K in total across 1 round, most recently a $425K Angel round in May 2025. Investors include AIR Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AngelAngel RoundMay 2025
$425K

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Devoted Health

Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...

Waltham, United States1001–5000Artificial Intelligence, Healthcare
Series FTotal funding$3.8BJan 2026
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Verily Life Sciences

Verily builds AI-native precision health platforms that help healthcare organizations harmonize d...

Dallas, United States1001–5000Artificial Intelligence, Healthcare
Corporate RoundTotal funding$3.0BMar 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CellRep on Indexed.vc
<a href="https://indexed.vc/companies/cellrep"><img src="https://indexed.vc/api/badge/company/cellrep" alt="CellRep on Indexed.vc" width="260" height="76" /></a>